BOSTON U.S. Senate Majority Leader Bill Frist, R.-Tenn., today called for drug companies to voluntarily restrict direct-to-consumer advertising efforts during new drugs’ first two years on the market.
He is also seeking a General Accountability Office review of Food and Drug Administration oversight of prescription drug activities and the industry’s spending on such ads.
“In recent years, spending on DTC advertising of prescription drugs has skyrocketed,” said Frist, in a statement. “This advertising can lead to inappropriate prescribing and fuel prescription drug spending.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in